10-Q quarterly report · filed Oct 29, 2026

Lilly (Eli) (LLY) Q3 2026 10-Q Quarterly Report

Short answer

Lilly (Eli) (LLY) filed its Q3 2026 10-Q quarterly report on Oct 29, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $24.4B (up 38.6% year over year) with net income of $6.5B.

Q3 2026 key financials · XBRL

Revenue
$24.4B
+38.6% YoY · +6.2% QoQ
Net income
$6.5B
+15.6% YoY · −9.1% QoQ
EPS (diluted)
$7.23
+16.4% YoY · −8.8% QoQ

Source: XBRL data from the Lilly (Eli) (LLY) Q3 2026 10-Q on SEC EDGAR. USD.

Lilly (Eli) Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $24,397M, up $6,796M YoY from $17,601M, driven by volume despite lower realized prices
  • Gross margin 83.9% vs 82.9% YoY, with gross margin dollars of $20,464M vs $14,593M
  • Best performer: Mounjaro revenue $10,723M vs $6,515M, up 64% YoY
  • Cash $4.9B vs $7.3B at December 31, 2025, with $18.2B deployed to business development
  • Near-term risks: Medicare uptake uncertainty, pricing pressure, counterfeit incretins, and additional manufacturing investment needs

Risk Factors

  • No material changes from the December 31, 2025 Form 10-K risk factors
  • Carried-forward risks remain the company’s material disclosed exposures

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Lilly (Eli) quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.